Please login to the form below

Not currently logged in
Email:
Password:

Strimvelis

This page shows the latest Strimvelis news and features for those working in and with pharma, biotech and healthcare.

Orchard surpasses IPO expectations, raising $200m

Orchard surpasses IPO expectations, raising $200m

Orchard gained ex-vivo gene therapy Strimvelis, a treatment for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), from the deal, along with a clinical programme for beta thalassaemia, which ... In having acquired Strimvelis

Latest news

More from news
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    pancreatitis. Then GSK’s Strimvelis followed in 2016 for a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). ... GSK has also had very limited success with Strimvelis and has now sold on the

  • Health on instalment Health on instalment

    Another EU drug, Strimvelis, targeting immune deficiency, retails for $665, 000.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The gene therapy revolution

    As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene therapy approved by the EMA (European Medicines ... https://www.ncbi.nlm.nih.gov/books/NBK1483/ (accessed

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics